Inclusion Criteria:

- At least 1 site of measurable disease

- Life expectancy >/= 12 weeks

- Adequate marrow and organ function

- Diagnosis of lung cancer, breast cancer, colorectal cancer, cholangiocarcinoma,
gastric cancer, pancreatic cancer, prostate cancer, uterine cancer, ovarian cancer,
esophageal cancer, or head and neck cancer

- Pathologically documented, definitively diagnosed, advanced solid tuor that is
refractory to standard treatment, for which no standard therapy is available, or the
subject refuses standard therapy

- Cancer must have at least one of the following PIK3CA mutations: E542K, E545K,
H1047R, H1047L. The PIK3CA mutation must be documented in a CLIA approved laboratory

Exclusion Criteria:

- Prior treatment with a P13K inhibitor

- Known hypersensitivity to BKM120 or its excipients

- Untreated brain metastases

- Acute or chronic liver, renal disease or pancreatitis

- Currently treated with drugs known to be moderate and strong inhibitors or inducers
of isoenzyme CYP3A

- Diarrhea >/= CTCAE grade 2

- Any concurrent severe and/or uncontrolled medical condition

- Active cardiac disease

- History of cardiac dysfunction

- Poorly controlled diabetes mellitus or steroid-induced diabetes mellitus

- Significant symptomatic deterioration of lung function

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of BKDM120 (e.g., ulcerative diseases, uncontrolled nausea,
vomiting, diarrhea, malabsorption syndrome, or small bowel resection)

- Currently taking therapeutic doses of warfarin sodium or any other
coumadin-derivative anticoagulant

- Pregnant or breast-feeding

- Known diagnosis of HIV infection

- History of another malignancy within 3 years, except cured basal cell carcinoma of
the skin or excised carcinoma in situ of the cervix

- Unable to swallow the medication in its prescribed form